Hank Kaplan ABRCC

    Clinical Researchers Showcase Series - February 2015

    Translational Medicine Research:

 View from the Trenches Newsletter

box_top.gif

Brought to you by:

Criterium Logo Alt Tag Line w Globe Banner 2

Translational science is motivated by the need to provide effective treatments to the right patients at the right doses for a specific disease indication). The term is used mostly in the health sciences and refers to real-time translation of bench science, conducted

only in a lab, to bedside clinical practice or dissemination

to population-based community interventions.

-  Source: NIH -- Read more


from the
Academic Breast Cancer Consortium

ABRCC Researcher Spotlight:

MEET Dr. Henry G. Kaplan, M.D.
Swedish Cancer Institute, Seattle WA

ABRCC Investigator


Dr. Henry "Hank" Kaplan, MD, is the Chief of Medical Oncology and Chief of the Medical Oncology Breast Service at Swedish.

 

Dr. Kaplan went to Medical School at the University of Rochester, NY. Did his Residency at the University of Washington, WA and a Fellowship with the National Cancer Institute/National Institutes of Health. Previously he was Chief Resident, Dept of Medicine: University of Washington, WA; Clinical Associate Professor, University of Washington; Clinical Professor of Medicine Brown University 1977-79; Adjunct Professor of Pharmacy, University of Rhode Island 1977-79; and Assistant Professor of Medicine, University of Washington 1979-1981. His Board Certifications include Internal Medicine and Oncology.

The primary focus of Dr. Kaplan’s research continues to be on breast cancer, although he is also continuing his work in hematological malignancies – cancers affecting blood, bone marrow and lymph nodes – and, more recently, in the area of targeted therapy for genomic mutation.

Dr. Henry Kaplan is the lead investigator for the several clinical trials currently at the Swedish Cancer Institute: 

http://www.swedish.org/physicians/henry-kaplan

He has received multiple faculty teaching awards and a Swedish Physician Recognition Award, AOA. He was recognized in Seattle Metropolitan magazine’s annual Top Doctors and Nurse Practitioners feature as top doc every year since 2006.  Dr. Kaplan was also voted "Top Doctors" in Seattle Magazine (2013, 2014) based on peer surveys from physicians in King, Pierce, Snohomish and Kitsap counties in Washington.

 

About Swedish Cancer Institute
As a Seattle-area leader in diagnosis, treatment and recovery since 1932, the Swedish Cancer Institute (SCI) cancer care network offers services to help you fight cancer—and win. Our team includes a host of oncologists—doctors focused exclusively on the care and treatment of cancer, using medication, radiation and other therapies. At our locations in and around the greater Seattle area, we work in a collaborative, multidisciplinary environment that focuses on the patient—not the disease. And even though we use some of the most advanced technologies and procedures, we also offer a wide range of complementary treatments and services that address your psychological, emotional and spiritual needs. The Swedish Cancer Institute has a new weapon in the fight against cancer. It's called personalized medicine -- the biggest news in cancer treatment in years. Learn more at http://www.swedish.org/services/cancer-institute

box_bottom.gif

About the CONSORTIA MODEL 
for Translational Research

The important conceptual difference between the two predominant research group approaches used today (a Clinical Trials Group vs. Consortia) is seen in this consortia model.  With its highly experienced clinical scientists, ABRCC becomes involved on an intellectual advisory level with every step of clinical investigation in a breast cancer study. Classical clinical trials groups "just run the study" with the main substantive role being patient accrual.

 

To read more on ABRCC and the details of why the consortia model creates fast results, please visit our website.


The Oncology Consortia of Criterium

The Oncology Consortia of Criterium Global CRO are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise:

  • AGICC:  Academic GI Cancer Consortium
  • AMyC:  Academic Myeloma Consortium
  • ATOMIC:  Academic Thoracic Oncology Medical Investigators Consortium
  • ABRCC:  Academic Breast Cancer Consortium

ABRCC Cube FULL Logo 2

Read more about Criterium Inc Global CRO

and The Oncology Consortia of Criterium on our website